The discovery of synthetic lethality between PARP enzymatic inhibition and BRCA1/2 mutations ultimately led to the rapid clinical translation of PARP inhibitors (PARPi) for the treatment of BRCA1/2-mutant breast cancers (Bryant et al, 2005; Farmer et al, 2005). Here, BRCA1 is linked to breast cancer.